- Molecular NameAminoglutethimide
- SynonymDl-Aminoglutethimide; P-Aminoglutethimide
- Weight232.283
- Drugbank_IDDB00357
- ACS_NO125-84-8
- Show 3D model
- LogP (experiment)2.029
- LogP (predicted, AB/LogP v2.0)1.36
- pkaN/A
- LogD (pH=7, predicted)1.35
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-2.07
- LogSw (predicted, AB/LogsW2.0)1.4
- Sw (mg/ml) (predicted, ACD/Labs)1.98
- No.of HBond Donors3
- No.of HBond Acceptors4
- No.of Rotatable Bonds2
- TPSA72.19
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn anti-steroid drug marketed under the tradename Cytadren by Novartis around the world. It blocks the production of steroids derived from cholesterol and is clinically used in the treatment of Cushing's syndrome and metastatic breast cancer. It is also a drug of abuse by body builders.
- Absorption_value100.0
- Absorption (description)Aminoglutethimide is readily absorbed after oral administration.
- Caco_2N/A
- Bioavailability95.0
- Protein binding23.0
- Volume of distribution (VD)1.4 L/kg
- Blood/Plasma Partitioning ratio (D_blood)Plasma:whole blood ratio, about 0.7.
- MetabollsmHepatic. Acetamidoglutethimide has been identified as a metabolite. Aminoglutethimide appears to induce its own metabolism.
- Half life12.5 h
- ExcretionAbout 10% of an oral dose is excreted in the urine as unchanged drug in 48 h
- Urinary ExcretionN/A
- ClerancePlasma clearance, about 1.3 mL/min/kg.
- ToxicityThe estimated minimum lethal dose is 5 g. LD50 (mouse) =625
- LD50 (rat)N/A
- LD50 (mouse)N/A